EA200100811A1 - Ацетиленистый сульфонамидтиол как ингибитор фнокф - Google Patents

Ацетиленистый сульфонамидтиол как ингибитор фнокф

Info

Publication number
EA200100811A1
EA200100811A1 EA200100811A EA200100811A EA200100811A1 EA 200100811 A1 EA200100811 A1 EA 200100811A1 EA 200100811 A EA200100811 A EA 200100811A EA 200100811 A EA200100811 A EA 200100811A EA 200100811 A1 EA200100811 A1 EA 200100811A1
Authority
EA
Eurasian Patent Office
Prior art keywords
sulphonamidtiol
fnokf
acetylene
inhibitor
sepsis
Prior art date
Application number
EA200100811A
Other languages
English (en)
Inventor
Джереми Ян Левин
Джеймс Минг Чен
Original Assignee
Американ Цианамид Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Американ Цианамид Компани filed Critical Американ Цианамид Компани
Publication of EA200100811A1 publication Critical patent/EA200100811A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/50—Organo-phosphines
    • C07F9/53—Organo-phosphine oxides; Organo-phosphine thioxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B53/00—Asymmetric syntheses

Abstract

Предложены соединения формулы В: (1a), (1b) и (1с), где переменные имеют определенные здесь значения, которые применимы при болезненных состояниях, медиируемых ФНО-α, таких как ревматоидный артрит, остеоартрит, сепсис, СПИД, язвенный колит, множественный склероз, болезнь Крона и дегенеративное разрушение хряща.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200100811A 1999-01-27 2000-01-27 Ацетиленистый сульфонамидтиол как ингибитор фнокф EA200100811A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23839399A 1999-01-27 1999-01-27
PCT/US2000/002143 WO2000044716A1 (en) 1999-01-27 2000-01-27 Acetylenic sulfonamide thiol tace inhibitors

Publications (1)

Publication Number Publication Date
EA200100811A1 true EA200100811A1 (ru) 2002-12-26

Family

ID=22897697

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200100811A EA200100811A1 (ru) 1999-01-27 2000-01-27 Ацетиленистый сульфонамидтиол как ингибитор фнокф

Country Status (21)

Country Link
EP (1) EP1149074B1 (ru)
JP (1) JP2002535386A (ru)
KR (1) KR20010101691A (ru)
CN (1) CN1224612C (ru)
AT (1) ATE280152T1 (ru)
AU (1) AU766192B2 (ru)
BR (1) BR0007727A (ru)
CA (1) CA2356480A1 (ru)
CZ (1) CZ20012545A3 (ru)
DE (1) DE60015079T2 (ru)
DK (1) DK1149074T3 (ru)
EA (1) EA200100811A1 (ru)
ES (1) ES2230064T3 (ru)
HK (1) HK1038915A1 (ru)
HU (1) HUP0105282A3 (ru)
IL (1) IL144347A0 (ru)
NO (1) NO20013638D0 (ru)
NZ (1) NZ512306A (ru)
PL (1) PL350420A1 (ru)
WO (1) WO2000044716A1 (ru)
ZA (1) ZA200105069B (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003033477A1 (en) * 2001-10-12 2003-04-24 Warner-Lambert Company Llc Alkynlated fused ring pyrimidine compounds as matrix metalloprotease-13 inhibitor
US6962922B2 (en) 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
MXPA04005927A (es) 2001-12-20 2004-11-01 Squibb Bristol Myers Co Derivados de alfa-(n-sulfonamido)acetamida como inhibidores del peptido beta-amiloideo.
US6747147B2 (en) 2002-03-08 2004-06-08 Warner-Lambert Company Oxo-azabicyclic compounds
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
US7199155B2 (en) 2002-12-23 2007-04-03 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors
US8084477B2 (en) 2007-10-31 2011-12-27 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8093276B2 (en) 2007-10-31 2012-01-10 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8044077B2 (en) 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
US8252821B2 (en) 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
BR112021006407A8 (pt) 2018-10-04 2022-12-06 Inst Nat Sante Rech Med uso de inibidores do egfr para ceratodermas

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0939629A4 (en) * 1996-07-22 2002-07-17 Monsanto Co THIOL-SULFONAMIDES AS METALLOPROTEINAS INHIBITORS
WO1998003164A1 (en) * 1996-07-22 1998-01-29 Monsanto Company Thiol sulfone metalloprotease inhibitors

Also Published As

Publication number Publication date
WO2000044716A1 (en) 2000-08-03
CN1337947A (zh) 2002-02-27
AU766192B2 (en) 2003-10-09
CN1224612C (zh) 2005-10-26
DE60015079D1 (de) 2004-11-25
CA2356480A1 (en) 2000-08-03
KR20010101691A (ko) 2001-11-14
NO20013638L (no) 2001-07-24
NZ512306A (en) 2003-10-31
ATE280152T1 (de) 2004-11-15
PL350420A1 (en) 2002-12-16
DE60015079T2 (de) 2005-03-03
BR0007727A (pt) 2001-10-30
NO20013638D0 (no) 2001-07-24
HUP0105282A3 (en) 2005-04-28
JP2002535386A (ja) 2002-10-22
IL144347A0 (en) 2002-05-23
EP1149074B1 (en) 2004-10-20
HUP0105282A2 (hu) 2002-05-29
HK1038915A1 (zh) 2002-04-04
CZ20012545A3 (cs) 2002-04-17
ES2230064T3 (es) 2005-05-01
DK1149074T3 (da) 2005-01-10
ZA200105069B (en) 2002-09-20
AU2741700A (en) 2000-08-18
EP1149074A1 (en) 2001-10-31

Similar Documents

Publication Publication Date Title
EA200100812A1 (ru) АЦЕТИЛЕНОВЫЕ, ОСНОВАННЫЕ НА α-АМИНОКИСЛОТАХ, ПРОИЗВОДНЫЕ СУЛЬФОНАМИДОВ ГИДРОКСАМОВЫХ КИСЛОТ - ИНГИБИТОРЫ ФЕРМЕНТОВ, КОНВЕРТИРУЮЩИХ ФАКТОР НЕКРОЗА ОПУХОЛЕЙ TNF-α (TACE)
EA200100811A1 (ru) Ацетиленистый сульфонамидтиол как ингибитор фнокф
ATE206409T1 (de) N-(1-alkyl-5-phenyl-2,3,4,5-tetrahydro-1-h- benzo(b)(1,5)-diazepin-3-yl)-acetamide
EA200300663A1 (ru) Антагонисты cxcr3
YU30100A (sh) Postupak za proizvodnju sintetičkih polimerizata vrlo malog sadržaja ostatka monomera, proizvodi po istom i njihova primena
EA199900643A1 (ru) Сульфамидные ингибиторы металлопротеаз
EA200200890A1 (ru) Применение ингибиторов il-18
EA200100807A1 (ru) Производные алкинилсодержащих гидроксамовых кислот и их применение в качестве ингибиторов tace
EA200200510A1 (ru) 4-карбоксиамино-2-этил-1,2,3,4-тетрагидрохинолин в кристаллической форме как ингибитор сетр
DE69626981D1 (de) N-(2-oxo-2,3,4,5-tetrahydro-1h-1,5-benzodiazepin-3-yl)-3-amide
EA200100607A1 (ru) 3,4,5-тризамещенные арилнитроны и содержащие их фармацевтические композиции
EA200000094A1 (ru) Способ получения замещенного пергидроизоиндола
EA199900385A1 (ru) Соединения 1-арил-2-ациламиноэтана и их применение в качестве антагонистов нейрокинина, в частности нейрокинина 1
EA200000544A1 (ru) Способ получения водорастворимых или водонабухающих полимеризатов с очень низким содержанием остаточного мономера, продукты, полученные согласно этому способу, и их применение
EA199800280A1 (ru) Новые производные 5-0-дезозаминил-6-0-метилэритронолида а, способ их получения и их использование при получении биологически активных продуктов
PT1144369E (pt) Acidos hidroxamicos de arilsulfonamidas acetilenicas e de amidas de acido fosfinico acetilenicas inibidores de tace
SE9202323D0 (sv) N-metylerad bis-4-piperidylfosfit
EA200100814A1 (ru) Применение ацетиленового орто-сульфонамида и фосфинамидозамещенных бициклических гетероарильных гидроксамовых кислот в качестве ингибиторов tace
DK0708762T3 (da) Fremgangsmåde til fremstilling af HIV protease-inhibitorer
EA200100808A1 (ru) ГИДРОКСАМОВЫЕ КИСЛОТЫ НА ОСНОВЕ АЦЕТИЛЕНОВОГО b-СУЛЬФОНАМИДО И АМИДА ФОСФИНОВОЙ КИСЛОТЫ, КАК ИНГИБИТОРЫ TACE
EA200100805A1 (ru) Ингибиторы tace на основе гетероарилацетиленсульфонамида и фосфинамида гидроксамовой кислоты
ATE214921T1 (de) Neuer kalium-kanal-agonist, der von trichoderma virens gewonnen wird
MY127110A (en) Process for producing amide compound
EA199800722A1 (ru) Способ получения 2-(тиозамещенных)-4-галогенацетофенонов